

# SANOFI S.A.

ISIN: FR0000120578

WKN: 12057

Asset Class: Stock

## Company

2022/09/30 17:36:22



Price

**78.40**

EUR

Difference

0.72%(0.56)



## Contact Details

SANOFI

Tel: 33-1-53-77-40-00

--

Fax: 33-1-53-77-44-03

54, rue La Boétie

Web: <http://www.sanofi.com>

75008 Paris

E-mail: [investor.relations@sanofi.com](mailto:investor.relations@sanofi.com)

## Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2021            |                        | 2020            |                        | 2019            |                        |
|---------------------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                       | Assets          | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| <b>Current assets</b>                 | 30,564,000,000  |                        | 33,703,000,000  |                        | 28,611,000,000  |                        |
| <b>Common stock capital</b>           |                 | 2,527,000,000          |                 | 2,518,000,000          |                 | 2,508,000,000          |
| <b>Fixed assets</b>                   | 89,678,000,000  |                        | 80,826,000,000  |                        | 84,125,000,000  |                        |
| <b>Equity capital of a company</b>    |                 | 69,031,000,000         |                 | 63,147,000,000         |                 | 59,108,000,000         |
| <b>Cash and cash equivalents</b>      | 10,098,000,000  |                        | 13,915,000,000  |                        | 9,742,000,000   |                        |
| <b>Accrued liabilities</b>            |                 | 6,430,000,000          |                 | 7,219,000,000          |                 | 7,353,000,000          |
| <b>Other assets</b>                   | -               |                        | -               |                        | -               |                        |
| <b>Current liabilities</b>            |                 | 21,295,000,000         |                 | 19,248,000,000         |                 | 20,381,000,000         |
| <b>Prepayments and accrued income</b> | -               |                        | -               |                        | -               |                        |
| <b>Non-current liabilities</b>        |                 | 29,916,000,000         |                 | 32,134,000,000         |                 | 33,247,000,000         |
| <b>Different income</b>               |                 | -                      |                 | -                      |                 | -                      |
| <b>Other liabilities</b>              |                 | 2,907,000,000          |                 | 2,469,000,000          |                 | 2,482,000,000          |
| <b>Total assets</b>                   | 120,242,000,000 | 120,242,000,000        | 114,529,000,000 | 114,529,000,000        | 112,736,000,000 | 112,736,000,000        |

## Balance notes

|                            | 2021   | 2020   | 2019    |
|----------------------------|--------|--------|---------|
| <b>Accounting standard</b> | IFRS   | IFRS   | IFRS    |
| <b>Employees</b>           | 95,442 | 99,412 | 100,409 |
| <b>Equity ratio</b>        | 57.70% | 55.26% | 52.58%  |
| <b>Debt-equity ratio</b>   | 73.31% | 80.95% | 90.17%  |

## Others

|                         | 2021   | 2020   | 2019  |
|-------------------------|--------|--------|-------|
| <b>Tax Expense Rate</b> | 19.98% | 13.13% | 4.93% |

**Income statement**

|  | 2021           | 2020           | 2019           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 37,761,000,000 | 36,041,000,000 | 36,126,000,000 |
| <b>Net income</b>  | 6,223,000,000  | 12,314,000,000 | 2,907,000,000  |
| <b>EBIT</b>  | 8,171,000,000  | 14,241,000,000 | 3,289,000,000  |
| <b>Operating income before taxes</b>                                 | 7,798,000,000  | 13,804,000,000 | 2,822,000,000  |
| <b>Cash Flow</b>   | 10,522,000,000 | 7,449,000,000  | 7,744,000,000  |
| <b>Net interest income</b>   | -373,000,000   | -437,000,000   | -467,000,000   |
| <b>Research and development expenses</b>                             | 5,689,000,000  | 5,527,000,000  | 6,015,000,000  |
| <b>Income taxes</b>  | 1,558,000,000  | 1,813,000,000  | 139,000,000    |
| <b>Result from investments in subsidiaries, associates and other</b> | 39,000,000     | 359,000,000    | 255,000,000    |
| <b>Revenues per employee</b>   | 395,643        | 362,542        | 359,788        |

**Board of Directors**

|                       |                               |
|-----------------------|-------------------------------|
| Serge Weinberg        | Chairman of Supervisory Board |
| Antoine Yver          | Member of Supervisory Board   |
| Emile Voest           | Member of Supervisory Board   |
| Thomas Südhof         | Member of Supervisory Board   |
| Wolfgang Laux         | Member of Supervisory Board   |
| Barbara Lavernos      | Member of Supervisory Board   |
| Carole Ferrand        | Member of Supervisory Board   |
| Christophe Babule     | Member of Supervisory Board   |
| Diane Souza           | Member of Supervisory Board   |
| Fabienne Lecorvaisier | Member of Supervisory Board   |
| Frédéric Oudéa        | Member of Supervisory Board   |
| Gilles Schnepf        | Member of Supervisory Board   |
| Lise Kingo            | Member of Supervisory Board   |
| Patrick Kron          | Member of Supervisory Board   |
| Rachel Duan           | Member of Supervisory Board   |
| Yann Tran             | Member of Supervisory Board   |

**Members of Management Board**

|                                       |                               |
|---------------------------------------|-------------------------------|
| Paul Hudson                           | Chairman of Managing Board    |
| John Reed                             | Member of Executive Committee |
| Arnaud Robert                         | Member of Executive Committee |
| Bill Sibold                           | Member of Executive Committee |
| Brendan O'Scallaghan                  | Member of Executive Committee |
| Jean-Baptiste Chasseloup de Chatillon | Member of Executive Committee |
| Julie Van Ongevalle                   | Member of Executive Committee |
| Karen Linehan                         | Member of Executive Committee |
| Natalie Bickford                      | Member of Executive Committee |
| Olivier Charmeil                      | Member of Executive Committee |
| Thomas Triomphe                       | Member of Executive Committee |